Platelet Activation Mechanisms in Cancer Biology

Platelets are increasingly recognised as active participants in tumour progression rather than mere bystanders of haemostasis. Tumour cells express procoagulant factors that trigger platelet activation and aggregation through engagement of surface receptors such as glycoprotein VI and integrin αIIbβ3, and through the local generation of thrombin and adenosine diphosphate. Upon activation, platelets release a repertoire of growth factors, chemokines and bioactive lipids that promote cancer cell survival, angiogenesis and evasion of immune surveillance. Among these lipids, products of arachidonic acid metabolism generated by platelet‐resident enzymes such as 12‐lipoxygenase yield 12(S)‐hydroxyeicosatetraenoic acid (12(S)‐HETE), which modulates endothelial integrity and enhances tumour cell invasive capacity. Physical interactions between platelet integrins and tumour cell surface proteins foster the formation of protective platelet cloaks around circulating tumour cells, facilitating metastatic seeding at distant sites. Conversely, shear‐driven platelet activation supports extravasation through vascular remodelling. Platelet‐derived microparticles further reinforce tumour cell plasticity and metabolic adaptation within the microenvironment, while interactions with leukocytes modulate the inflammatory milieu. Integrative studies combining proteomic, lipidomic and in vivo models have refined our understanding of platelet‐driven mechanisms in cancer progression, uncovering therapeutic opportunities to disrupt these pathogenic crosstalk pathways.

Research from Nature Portfolio

No recent Nature Portfolio content available.

Platelet Activation Mechanisms in Cancer Biology publication trend

The graph below shows the total number of articles in platelet activation mechanisms in cancer biology across all publications each year (not limited to Nature Index journals).

Technical terms

Platelet activation: The process by which resting platelets become adhesive, secrete granule contents and expose procoagulant surfaces in response to agonists.

Eicosanoid: A class of bioactive lipid mediators derived from arachidonic acid that regulate inflammation, vascular tone and cell signalling.

12-Lipoxygenase (12-LOX): An enzyme in platelets that oxygenates arachidonic acid to form 12-hydroperoxyeicosatetraenoic acid, the precursor of 12(S)-HETE.

12(S)-HETE: A hydroxylated eicosanoid produced by 12-LOX that modulates endothelial function and tumour cell invasiveness.

Integrin β4: A cell-surface adhesion receptor subunit that mediates epithelial and carcinoma cell attachment to the extracellular matrix and transduces survival signals.

Angiogenesis: The formation of new blood vessels from pre-existing vasculature, a critical process for tumour growth and metastasis.

ERK1/2: Extracellular signal-regulated kinases, key components of the MAPK pathway that regulate cell proliferation, survival and migration.

References

1. Convergence of eicosanoid and integrin biology: 12-lipoxygenase seeks a partner. Molecular Cancer (2015).
2. Mechanisms Regulating Tumor Angiogenesis by 12-Lipoxygenase in Prostate Cancer Cells*. Journal of Biological Chemistry (2006).
3. Eicosanoid Activation of Extracellular Signal-regulated Kinase1/2 in Human Epidermoid Carcinoma Cells*. Journal of Biological Chemistry (2000).